skip to Main Content

San Carlos, CA, November 18, 2019 – FlemingMartin is pleased to announce that Natera (NASDAQ: NTRA), a worldwide genetic testing and diagnostics company, has hired Kevin Masukawa as their Vice President of Oncology Marketing.

Kevin is an experienced commercial leader with a demonstrated history of shaping and delivering strategically integrated (clinical and non-clinical) solutions to customers. Kevin brings 12+ years of oncology expertise to Natera from his multiple roles across Genentech. Over his tenure at Genentech, Kevin earned multiple promotions and most recently served as Director of Marketing for the Oncology Pipeline and Cross Business Unit Field Teams (spanning Account Management & Biomarker Testing).

Earlier in his career, Kevin worked with companies in the therapeutics, life science research tools, medical device, and clinical diagnostics industries at L.E.K. Consulting. Kevin received his Ph.D. in Chemistry and Chemical Biology from the University of California, San Francisco, and earned his B.S. in Chemistry and Biochemistry from the University of California, San Diego.

 

Natera is a worldwide genetic testing and diagnostics company that’s changing how doctors and patients manage genetic disease. Natera’s Signatera technology is the first and only circulating tumor DNA (ctDNA) surveillance tool that detects molecular residual disease (MRD) for greater clinical confidence when assessing disease recurrence or treatment response in solid tumors. To learn more, visit natera.com.

FlemingMartin is a leading retained executive search firm with offices in Northern and Southern California. FlemingMartin partners with Boards, Private Equity Firms, and CEOs of companies to build successful execution-focused management teams. The Firm’s principals are trusted advisors and business partners who enable companies to gain powerful, far-reaching, and lasting contributions from their executive-level human capital. flemingmartin.com

Back To Top